| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
13636370518 |
| Email: |
shyysw007@163.com |
| Products Intro: |
Product Name:Rilotumumab (anti-HGF)
CAS:872514-65-3
Purity:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human I Package:5mg Remarks:K10763
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Rilotumumab
CAS:872514-65-3
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Rilotumumab
CAS:872514-65-3
Purity:95% Package:1mg;1g;100g
|
Rilotumumab manufacturers
- Rilotumumab
-
- $255.00
-
2026-07-27
- CAS:872514-65-3
- Purity: 97.51% (SEC-HPLC)
- Supply Ability: 10g
|
| | Rilotumumab Basic information |
| Product Name: | Rilotumumab | | Synonyms: | Rilotumumab;Research Grade Rilotumumab(DHD03702);Rilotumumab (anti-HGF);AMG 102;Research Grade Rilotumumab | | CAS: | 872514-65-3 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Rilotumumab Structure]() |
| | Rilotumumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Rilotumumab Usage And Synthesis |
| Description | Rilotumumab is an anti-HGF antibody that prevents ligand binding to MET and its activation. | | Uses | Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research[1][2]. | | Clinical Use | A phase I/II trial of rilotumumab in combination with erlotinib was evaluated in previously treated NSCLC patients with metastatic disease. The results indicated a favorable safety profile and success in terms of disease control rate. A phase Ib/II trial of rilotumumab or ganitumab in combination with etoposide and carboplatin or cisplatin was evaluated in extensive-stage SCLC patients. | | in vivo | Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once two days; 11 d) treatment inhibits glioma cell growth in vivo[2]. | Animal Model: | 6-8-week-old BALB/c nu/nu female mice subcutaneous injected with U87MG.vIII cells[2] | | Dosage: | 1.5 mg/kg | | Administration: | Intraperitoneal injection; 1.5 mg/kg; once two days; 11 days | | Result: | Reduced U87MG.vIII xenograft growth (P=0.0002) compared with vehicle-treated xenografts (P=0.0001). |
| | References | [1] Ryan CJ, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013 Jan 1;19(1):215-24. DOI:10.1158/1078-0432.CCR-12-2605
[2] Greenall SA, et al. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene. 2015 Oct 8;34(41):5277-87. DOI:10.1038/onc.2014.448 |
| | Rilotumumab Preparation Products And Raw materials |
|